Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $2.9 million.

  • Coeptis Therapeutics Holdings' Net Cash Flow rose 79722.24% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 147599.89%. This contributed to the annual value of -$936249.0 for FY2024, which is 5968.21% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Net Cash Flow of $2.9 million as of Q3 2025, which was up 79722.24% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Net Cash Flow peaked at $5.0 million during Q3 2022, and registered a low of -$4.2 million during Q4 2021.
  • Over the past 5 years, Coeptis Therapeutics Holdings' median Net Cash Flow value was -$122205.0 (recorded in 2021), while the average stood at -$92658.5.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 844229.62% in 2022, then plummeted by 114915.83% in 2024.
  • Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' Net Cash Flow stood at -$4.2 million in 2021, then grew by 14.09% to -$3.6 million in 2022, then soared by 101.61% to $57624.0 in 2023, then plummeted by 1149.16% to -$604567.0 in 2024, then surged by 581.63% to $2.9 million in 2025.
  • Its Net Cash Flow stands at $2.9 million for Q3 2025, versus -$2.3 million for Q2 2025 and $3.7 million for Q1 2025.